Capital International, Inc. Allakos Inc. Transaction History

Capital International, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $11.4 Million - $16.4 Million	-148,487 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $800,002 - $1.07 Million	-9,371 Reduced 5.94%	148,487 $12.7 Million
Q1 2021 May 14, 2021	SELL	$109.73 - $153.66 $1.85 Million - $2.59 Million	-16,882 Reduced 9.66%	157,858 $18.1 Million
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $138,548 - $265,415	-1,741 Reduced 0.99%	174,740 $24.5 Million
Q3 2020 Nov 13, 2020	BUY	$66.43 - $90.99 $9,964 - $13,648	150 Added 0.09%	176,481 $14.4 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $4,007 - $7,342	-91 Reduced 0.05%	176,331 $12.7 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $122,703 - $257,569	-2,758 Reduced 1.54%	176,422 $7.85 Million
Q4 2019 Feb 18, 2020	BUY	$66.49 - $137.73 $11.9 Million - $24.7 Million	179,180 New	179,180 $17.1 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.